← Back to patent-cliff list
CAS 501-53-1
benzyl carbonochloridate(Phenylmethyl)carbonochloridate
Codes: RIVA-022, (VII)101438-22-a, Vornorexant-004
Application context (from source-drug indications)
Pulmonary embolismRivaroxabanStrokeRivaroxabanCongenital heart defectRivaroxabanThrombosisRivaroxabanVenous thromboembolismRivaroxabanCoronary artery diseaseRivaroxabanBreast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylatePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxelInsomnia and sleep disordersVornorexantHepatic function declineVornorexant睡眠呼吸暂停Vornorexant
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Rivaroxaban | Tier A — Act now | 2026 |
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
| Vornorexant | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2-chloroacetyl chloride→4-(4-nitrophenyl)morpholin-3-one→4-(4-aminophenyl)morpholin-3-one→5-chlorothiophene-2-carbonyl chloride→2-(phenylamino)ethan-1-ol→4-phenylmorpholin-3-one→benzyl carbonochloridate→benzyl (4-(3-oxomorpholino)phenyl)carbamate→(R)-oxiran-2-ylmethyl butyrate→(R)-4-(4-(5-(hydroxymethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one→(R)-(2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl methanesulfonate→2-methylpropan-2-amine→(S)-4-(4-(5-((tert-butylamino)methyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one→(S)-N-(tert-butyl)-5-chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)thiophene-2-carboxamide
(2R,3S)-3-phenyloxirane-2-carboxylic acid→(2-Hydroxyethyl)trimethylsilane→2-(trimethylsilyl)ethyl (2R,3S)-3-phenyloxirane-2-carboxylate→2-(trimethylsilyl)ethyl (2S,3S)-3-bromo-2-hydroxy-3-phenylpropanoate→alpha-Chlorobenzaldehyde→2-(trimethylsilyl)ethyl (2R,3S)-3-azido-2-hydroxy-3-phenylpropanoate→2-(trimethylsilyl)ethyl (2R,3S)-3-amino-2-hydroxy-3-phenylpropanoate→(Phenylmethyl)carbonochloridate→2-(trimethylsilyl)ethyl (2R,3S)-3-{[(benzyloxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate→2-(trimethylsilyl)ethyl (2R,3S)-2-(benzoyloxy)-3-{[(benzyloxy)carbonyl]amino}-3-phenylpropanoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-Bis(acetyloxy)-1,15-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-15-{[(2R,3S)-2-(benzoyloxy)-3-{[(benzyloxy)carbonyl]amino}-3-phenylpropanoyl]oxy}-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate
(2R,3S)-3-phenyloxirane-2-carboxylic acid→(2-Hydroxyethyl)trimethylsilane→2-(trimethylsilyl)ethyl (2R,3S)-3-phenyloxirane-2-carboxylate→2-(trimethylsilyl)ethyl (2S,3S)-3-bromo-2-hydroxy-3-phenylpropanoate→alpha-Chlorobenzaldehyde→2-(trimethylsilyl)ethyl (2R,3S)-3-azido-2-hydroxy-3-phenylpropanoate→2-(trimethylsilyl)ethyl (2R,3S)-3-amino-2-hydroxy-3-phenylpropanoate→(Phenylmethyl)carbonochloridate→2-(trimethylsilyl)ethyl (2R,3S)-3-{[(benzyloxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate→2-(trimethylsilyl)ethyl (2R,3S)-2-(benzoyloxy)-3-{[(benzyloxy)carbonyl]amino}-3-phenylpropanoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-Bis(acetyloxy)-1,15-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-15-{[(2R,3S)-2-(benzoyloxy)-3-{[(benzyloxy)carbonyl]amino}-3-phenylpropanoyl]oxy}-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate
3-aminopropan-1-ol→2-oxoacetic acid→1,3-oxazinane-2-carboxylic acid→benzyl carbonochloridate→3-((benzyloxy)carbonyl)-1,3-oxazinane-2-carboxylic acid→(R)-2-amino-2-phenylethan-1-ol→(S)-3-((benzyloxy)carbonyl)-1,3-oxazinane-2-carboxylic acid, (R)-2-amino-2-phenylethan-1-ol→(S)-3-((benzyloxy)carbonyl)-1,3-oxazinane-2-carboxylic acid→3-benzyl 2-methyl (S)-1,3-oxazinane-2,3-dicarboxylate→methyl (S)-1,3-oxazinane-2-carboxylate→5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl chloride→methyl (S)-3-(5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl)-1,3-oxazinane-2-carboxylate→(S)-(2-(hydroxymethyl)-1,3-oxazinan-3-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone→5-fluoro-2-(1-(methylsulfonyl)-1H-pyrazol-3-yl)pyridine→1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole→2-chloro-5-fluoropyridine→5-fluoro-2-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)pyridine→5-fluoro-2-(1H-pyrazol-3-yl)pyridine→5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | 4-(4-Aminophenyl)morpholin -3-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | (S)-(+)-N-(2,3-Epoxypropyl)phthalimide Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 5-Chlorothiophene-2-carboxylic acid Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 5-Chlorothiophene-2-carbonyl chloride Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2-[[(5S)-2-0x0-3-[4-(3-0xo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-1H-isoindole-1,3(2H)-dione Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 4-[4-[(5S)-5-(Aminomethyl)-2-0xo-3-oxazolidinyl]phenyl] -3-morpholinone hydrochloride Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 2-[(2R)-2-Hydroxy-3-[[4-(3-oxo-4-Morpho linyl)phenyl]aMino]propyl]-1H-isoindole-1 ,3(2H)-dione Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.